Trial · NCT06326684
Suvorexant and Alcohol
NCT06326684, Early phase 1, Recruiting, William Stoops
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Suvorexant and Alcohol. Trials, record NCT06326684. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06326684
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Suvorexant and Alcohol
- NCT number
- NCT06326684
- Status
- Recruiting
- Phases
- Early phase 1
- Enrollment
- 30 participants, estimated
- Lead sponsor
- William Stoops
- Conditions
- Alcohol Use Disorder
- Interventions
- Alcohol, Placebo, Suvorexant, Suvorexant
- First posted
- 2024-03-22
- Last updated
- 2026-06-08
Source ClinicalTrials.gov
Registered outcomes13
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Reinforcing Effects of Alcohol | 6 times over approximately 3 week inpatient admission. | Number of Times Subjects Choose Alcohol (Maximum of 5 Choices) Over Money |
| Secondary | Craving | 6 times over approximately 3 week inpatient admission. | Subjects will report their craving during 6 sessions while they are admitted to our inpatient unit. Measured using a 10 point craving questionnaire with higher scores meaning greater craving. |
| Secondary | Mood | 6 times over approximately 3 week inpatient admission. | Subjects will complete the Profile of Mood States during 6 sessions while they are admitted to our inpatient unit. Scores range from 0 to 4 with higher scores indicating stronger mood. |
| Secondary | Alcohol Response | 6 times over approximately 3 week inpatient admission. | Subjects will complete the Biphasic Alcohol Effects Scale during 6 sessions while they are admitted to our inpatient unit. Scores range from 0 to 10 with higher scores indicating greater responses. |
| Secondary | Heart rate | Daily over approximately 3 week inpatient admission. | Beats per minute. Measured daily during inpatient admission. |
| Secondary | Blood pressure | Daily over approximately 3 week inpatient admission. | mm Hg. Measured daily during inpatient admission. |
| Secondary | Breath Alcohol Level | Daily over approximately 3 week inpatient admission. | Percent. Measured daily during inpatient admission. |
| Secondary | Temperature | Daily over approximately 3 week inpatient admission. | Degrees Fahrenheit. Measured daily during inpatient admission. |
| Secondary | Side Effects | Daily over approximately 3 week inpatient admission. | Subjects will complete a side effects questionnaire daily while they reside on the inpatient unit. Side Effects questions will query subjects about common effects of centrally active medications. |
| Secondary | Delay Discounting | 6 times over approximately 3 week inpatient admission. | Subjects will complete the delay discounting task during 6 sessions while they are admitted to our inpatient unit. Responses will be used to calculate discounting slope (i.e., K). |
1 to 10 of 13Source ClinicalTrials.gov
See all 13 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants1
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years |
|---|---|---|---|---|---|
| R01AA030775 | Influence of Orexin Antagonism on Motivation for Alcohol | STOOPS, WILLIAM WALTON | UNIVERSITY OF KENTUCKY | NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM | 2024 to 2025 |
Source NIH RePORTER
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests4
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|---|---|
| 1-Back Task | Secondary outcome | ConductCognition |
| 2-Back Task | Secondary outcome | ConductCognition |
| Delay Discounting | Secondary outcome | ConductCognition |
| Stop-Signal Task | Secondary outcome | ConductCognition |
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06326684
GET https://conductscience.org/api/trials/v1/NCT06326684/registered